ENTRY       D10459                      Drug
NAME        Empagliflozin (JAN/USAN/INN);
            Jardiance (TN)
PRODUCT     JARDIANCE (A-S Medication Solutions)
            JARDIANCE (A-S Medication Solutions)
            JARDIANCE (A-S Medication Solutions)
            JARDIANCE (A-S Medication Solutions)
            JARDIANCE (Aphena Pharma Solutions - Tennessee)
            JARDIANCE (Boehringer Ingelheim Pharmaceuticals)
            JARDIANCE (Cardinal Health 107)
FORMULA     C23H27ClO7
EXACT_MASS  450.1445
MOL_WEIGHT  450.9093
CLASS       Antidiabetic agent
             DG02044  Hypoglycemic agent
              DG01794  SGLT2 inhibitor
            Metabolizing enzyme substrate
             DG02924  UGT substrate
              DG03184  UGT1A3 substrate
              DG03186  UGT1A8 substrate
              DG03188  UGT1A9 substrate
              DG03190  UGT2B7 substrate
            Transporter substrate
             DG01665  ABCB1 substrate
             DG01913  ABCG2 substrate
REMARK      Same as: C22194
            Therapeutic category: 2190 3969
            ATC code: A10BK03
            Product: D10459<JP/US>
            Product (mixture): D10588<JP/US> D10752<US> D11856<US>
EFFICACY    Antidiabetic, SGLT-2 inhibitor
  DISEASE   Type 2 diabetes mellitus [DS:H00409]
COMMENT     Phlorizin derivative
            Treatment of type 2 diabetes
TARGET      SLC5A2 (SGLT2) [HSA:6524] [KO:K14382]
METABOLISM  Enzyme: UGT2B7 [HSA:7364], UGT1A3 [HSA:54659], UGT1A8 [HSA:54576], UGT1A9 [HSA:54600]
            Transporter: ABCB1 [HSA:5243], ABCG2 [HSA:9429]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             A ALIMENTARY TRACT AND METABOLISM
              A10 DRUGS USED IN DIABETES
               A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
                A10BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors
                 A10BK03 Empagliflozin
                  D10459  Empagliflozin (JAN/USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Blood Glucose Regulators
              Antidiabetic Agents
               Sodium-Glucose Co-Transporter 2 (SGLT2) Inhbitor
                Empagliflozin
                 D10459  Empagliflozin (JAN/USAN/INN)
             Cardiovascular Agents
              Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i)
               Empagliflozin
                D10459  Empagliflozin (JAN/USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              21  Cardiovascular agents
               219  Miscellaneous
                2190  Miscellaneous
                 D10459  Empagliflozin (JAN/USAN/INN)
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               396  Antidiabetic agents
                3969  Others
                 D10459  Empagliflozin (JAN/USAN/INN)
            Drug groups [BR:br08330]
             Antidiabetic agent
              DG02044  Hypoglycemic agent
               DG01794  SGLT2 inhibitor
                D10459  Empagliflozin
             Metabolizing enzyme substrate
              DG02924  UGT substrate
               DG03184  UGT1A3 substrate
                D10459  Empagliflozin
               DG03186  UGT1A8 substrate
                D10459  Empagliflozin
               DG03188  UGT1A9 substrate
                D10459  Empagliflozin
               DG03190  UGT2B7 substrate
                D10459  Empagliflozin
             Transporter substrate
              DG01665  ABCB1 substrate
               D10459  Empagliflozin
              DG01913  ABCG2 substrate
               D10459  Empagliflozin
            Drug classes [BR:br08332]
             Antidiabetic agent
              DG01794  SGLT2 inhibitor
               D10459  Empagliflozin
              DG02044  Hypoglycemic agent
               D10459  Empagliflozin
            Target-based classification of drugs [BR:br08310]
             Transporters
              Solute carrier family
               SLC5
                SLC5A2 (SGLT2)
                 D10459  Empagliflozin (JAN/USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10459
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10459
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10459
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10459
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D10459
             Drug transporters
              D10459
DBLINKS     CAS: 864070-44-0
            PubChem: 172232552
            ChEBI: 82720
            PDB-CCD: 7R3
ATOM        31
            1   C8y C    15.1431  -17.5925
            2   C8x C    15.1431  -18.9937
            3   C8x C    16.3342  -19.6944
            4   C8y C    17.5953  -18.9937
            5   C8y C    17.5953  -17.5925
            6   C8x C    16.3342  -16.8919
            7   C1b C    18.7864  -16.8919
            8   C8y C    20.0475  -17.5925
            9   C8x C    20.0475  -18.9937
            10  C8x C    21.2385  -19.6944
            11  C8y C    22.4296  -18.9937
            12  C8x C    22.4296  -17.5925
            13  C8x C    21.2385  -16.8919
            14  X   Cl   18.7864  -19.6944
            15  O2a O    23.6207  -19.6944
            16  C1y C    24.8117  -18.9937
            17  C1y C    13.9521  -16.8919
            18  O2x O    13.9521  -15.4906
            19  C1y C    12.6909  -14.7900
            20  C1y C    11.4999  -15.4906
            21  C1y C    11.4999  -16.8919
            22  C1y C    12.6909  -17.5925
            23  O1a O    12.6909  -18.9937
            24  O1a O    10.3088  -14.7900
            25  O1a O    10.3088  -17.5925
            26  C1b C    12.6909  -13.3888
            27  O1a O    13.9521  -12.6881
            28  C1x C    26.0964  -19.5532
            29  O2x O    27.0256  -18.5043
            30  C1x C    26.3151  -17.2965
            31  C1x C    24.9468  -17.5990
BOND        34
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     5   7 1
            8     7   8 1
            9     8   9 2
            10    9  10 1
            11   10  11 2
            12   11  12 1
            13   12  13 2
            14    8  13 1
            15    4  14 1
            16   11  15 1
            17   16  15 1 #Up
            18   17   1 1 #Up
            19   17  18 1
            20   18  19 1
            21   19  20 1
            22   21  20 1
            23   21  22 1
            24   22  17 1
            25   22  23 1 #Down
            26   20  24 1 #Down
            27   21  25 1 #Up
            28   19  26 1 #Up
            29   26  27 1
            30   16  28 1
            31   28  29 1
            32   29  30 1
            33   30  31 1
            34   16  31 1
///
